Over the last four quarters, the company has surpassed consensus EPS estimates two times. ADC Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $18.84 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.58$17.41 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the ...